Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
On July 1, 2021, Johnson & Johnson (NYSE: JNJ) announced strong data supporting its single-shot COVID-19 vaccine's efficacy against the Delta variant, demonstrating persistent immune response lasting at least eight months. The vaccine showed neutralizing antibody activity higher against the Delta variant than previously seen with the Beta variant. The ENSEMBLE trial reported 85% effectiveness against severe illness. The vaccine is available globally on a not-for-profit basis during the pandemic, having received Emergency Use Authorization in the U.S. and Conditional Marketing Authorization in Europe.
Johnson & Johnson (NYSE: JNJ) will conduct a conference call for investors on July 21 at 8:30 a.m. ET to discuss its second-quarter results. Hosted by Joseph J. Wolk, CFO, and Christopher DelOrefice, VP of Investor Relations, the call will also feature Alex Gorsky, CEO. Interested parties can access the call via webcast on the company's website, or by telephone at designated numbers. A replay will be available until August 4. The press release will be issued at 6:45 a.m. ET on the same day.
Johnson & Johnson (NYSE: JNJ) released its 2020 Health for Humanity Report on June 9, 2021, detailing its environmental, social, and governance (ESG) performance. The report highlights progress towards the company's 2020 Goals, its response to COVID-19, and new 2025 Goals, emphasizing health equity and community support. Notable initiatives include a $50 million commitment to health workers and advancements in healthcare access. The report adheres to GRI Standards and includes SASB and TCFD disclosures, showcasing JNJ's dedication to transparency and sustainable value creation.
Johnson & Johnson (NYSE: JNJ) announced a collaboration with the WHO and the government of Sierra Leone to administer its Ebola vaccine regimen as part of an early access clinical program. This initiative aims to prevent further Ebola spread in West Africa, especially following a resurgence of cases in Guinea. The vaccine regimen has received WHO Prequalification, enhancing its accessibility in affected regions. The program targets health workers and vulnerable populations, with plans to vaccinate up to 200,000 individuals. Johnson & Johnson aims to bolster global health preparedness against infectious diseases.
Johnson & Johnson (JNJ) announced the resumption of its COVID-19 single-shot vaccine for adults in the U.S. under Emergency Use Authorization (EUA) following CDC and FDA approval. This decision comes after evaluating a rare blood clotting risk. The vaccine demonstrated 66.1% effectiveness against moderate to severe disease in the Phase 3 ENSEMBLE study. The company plans to file for a Biologics License Application later in 2021. Health authorities continue to monitor safety, emphasizing the need for prompt medical attention for specific symptoms. Updated EUA fact sheets are now available.
Johnson & Johnson (NYSE: JNJ) announced on April 20, 2021, that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee confirmed the positive benefit-risk profile of its COVID-19 vaccine. Following the review of rare adverse events, the company will update vaccine information to include guidance on diagnosing and managing these cases. Shipments of the Janssen COVID-19 vaccine will resume in the EU, Norway, and Iceland. The vaccine demonstrated 85% effectiveness in preventing severe disease during the ENSEMBLE Phase 3 trial, with continued monitoring by health authorities.
Johnson & Johnson (NYSE: JNJ) reported strong first-quarter 2021 results, with reported sales reaching $22.32 billion, representing a 7.9% increase from $20.69 billion in 2020. Net earnings rose to $6.20 billion, up 6.9% year-over-year, resulting in an EPS of $2.32. The Pharmaceutical segment led growth with a 9.6% increase, driven by key products like DARZALEX and STELARA. Medical Devices also saw an 8.8% growth, aided by recovery from COVID impacts. However, Consumer Health segment sales declined 2.3% due to prior year comparisons.
Johnson & Johnson (NYSE: JNJ) has announced a 5.0% increase in its quarterly dividend, raising it from $1.01 to $1.06 per share. This marks the 59th consecutive year of dividend increases, reflecting the company's strong financial position and confidence in future growth. The annualized dividend is now $4.24 per share, up from $4.04. The next dividend is payable on June 8, 2021, to shareholders recorded by May 25, 2021, with an ex-dividend date of May 24, 2021.
Johnson & Johnson (NYSE: JNJ) has signed an agreement with the African Vaccine Acquisition Trust (AVAT) to supply up to 400 million doses of its single-shot COVID-19 vaccine to African Union member states. Initial deliveries are set for Q3 2021, pending regulatory approvals. The vaccine has shown a 67% reduction in symptomatic COVID-19 and is 85% effective at preventing severe disease. J&J's vaccine is designed for wide distribution, remaining stable at common refrigeration temperatures, enhancing its accessibility in remote areas.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
